The addition of atezolizumab to neoadjuvant trastuzumab plus pertuzumab (HP) and chemotherapy led to a numerical, but not statistically significant, increase in pathologic complete response vs HP/chemotherapy alone in patients with HER2-positive operable breast cancer.
Preliminary study results examining the bispecific antibody, CDK4/6 inhibitor, and hormone therapy combination in patients with advanced breast cancer were presented at SABCS.
Clinical, transcriptomic, and genomic differences that may contribute to aggressive tumor biology were observed between Latin-American and non-Hispanic White patients with breast cancer.
The MammaPrint and BluePrint tests may be able to predict which patients with HR-positive, HER2-negative breast cancer are most likely to respond to neoadjuvant chemotherapy.
After more than 8 years of follow-up, T-DM1 continued to improve invasive disease-free survival and overall survival in patients with HER2-positive early breast cancer that had residual invasive disease.
The brain-penetrant oral selective estrogen receptor degrader SIM0270 exhibited a favorable safety profile and early signals of antitumor activity in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer, including those with ESR1 mutations.
Adjuvant ribociclib plus standard non-steroidal aromatase inhibitors improved invasive disease-free survival in HR-positive, HER2-negative early breast cancer, compared with nonsteroidal aromatase inhibitors alone.
Improvement in progression-free-survival was demonstrated across all relevant subgroups in patients with ER-positive/HER2-negative, ESR1-mutated advanced or metastatic breast cancer.
Stephanie L. Graff, MD, discusses what a community oncologist should know about her presentation on the Signatera assay in patients with hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer after adjuvant abemaciclib and endocrine therapy.
Anastrozole or fulvestrant plus fam-trastuzumab deruxtecan-nxki showed promising antitumor activity in patients with chemotherapy-naïve, HER2-low, hormone receptor-positive metastatic breast cancer.
Early findings from the DEBBRAH study suggest that fam-trastuzumab deruxtecan-nxki shows potential in treating patients with advanced HER2-positive, HER2-low breast cancer, including those with leptomeningeal carcinomatosis.
Datopotamab deruxtecan demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with chemotherapy in patients with previously treated, hormone receptor-positive/HER2-negative inoperable or metastatic breast cancer.
The RELIEVE study looked at real-world patients receiving trastuzumab deruxtecan based on HER2 expression status and time to next treatment including in those whose HER2 status changed during course of treatment.
Naomi Dempsey, MD, discusses her poster presented at the 2023 San Antonio Breast Cancer Symposium analyzing the correlation of the Breast Cancer Index and patient risk factors.
Accurately stratifying hormone receptor–positive, HER2-negative breast cancer using BluePrint and MammaPrint assays demonstrated comparable 3-year recurrence-free survival rates between Black and White patients despite disparities in the distribution of molecular subtypes.
The introduction of tucatinib to ado-trastuzumab emtansine significantly improved progression-free survival vs placebo plus T-DM1 in patients with previously treated HER2-positive metastatic breast cancer.
Maintenance pembrolizumab plus olaparib did not improve progression-free or overall survival in patients with locally recurrent inoperable or metastatic triple-negative breast cancer.
Adding pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab with endocrine therapy demonstrated improvements pathologic complete responses in key subsets of patients with early-stage, high-risk, estrogen receptor–positive/HER2-negative breast cancer.
Patients with hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer given abemaciclib for 2 years in addition to endocrine therapy demonstrated an association between ctDNA positivity and disease recurrence.
Patient-reported outcomes of the CAPItello-291 study of capivasertib plus fulvestrant showed a positive benefit-risk profile for the combination in patients with HR-positive, HER2-negative advanced breast cancer.
Senthil Damodaran, MD, PhD, discusses data from a phase 2 trial of futibatinib in patients with metastatic HR-positive/HER2-negative breast cancer with FGFR1 amplifications.
Prospective models show a drop in the cost of running sentinel lymph node assessments when artificial intelligence is used.
Adding ribociclib to endocrine therapy shows efficacy and tolerability for those with hormone receptor–positive, HER2-negative advanced breast cancer, even in older patients.
In an interview with Targeted Oncology, Neeraj Agarwal, MD, discussed findings from the TITAN trial which were presented at ESMO 2023.
In an interview with Targeted Oncology, Jeff Stein, PhD, discussed the challenges and prospects of CD73-targeting agents.
In an interview with Targeted Oncology, Chris Haqq, MD, PhD, discussed the potential use of cancer vaccines in patients with KRAS-mutated pancreatic and colon cancer.
Results from a phase 1/2a trial showed that plixorafenib had potential regarding safety and efficacy in BRAF-mutated solid tumors, especially in primary central nervous system tumors.
The combination of olaptesed pegol, bevacizumab, and radiotherapy showed an improvement in overall survival among patients with glioblastoma, according to findings from a phase 1/2 study.
Carlos Rojas, MD, discusses preliminary findings from a phase 1 trial which of MK-1084 alone and with pembrolizumab in patients with advanced solid tumors and metastatic non–small cell lung cancer.